Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
December 14, 2022 01:54 PM EST
Deals
Pharma

No­var­tis of­floads five eye drugs in deal worth up to $175M

Katherine Lewin

News Reporter

Eye care phar­ma com­pa­ny Har­row said this morn­ing that it’s ac­quir­ing the US rights to five dif­fer­ent drugs from the Swiss phar­ma No­var­tis for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times